Protara Therapeutics (TARA)

Protara Therapeutics (TARA) Income Statement


Protara Therapeutics Income Statement

Last quarter (Q2 2023), Protara Therapeutics's total revenue was $4.00K, an increase of Infinity% from the same quarter last year. In Q2, Protara Therapeutics's net income was $-11.29M. See Protara Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 21.00K$ 17.00K$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
Gross Profit
$ 21.00K$ 17.00K----
Operating Expense
$ 39.84M$ -67.06M$ 47.49M$ 34.44M$ 7.83M$ 21.37M
Operating Income
$ -39.84M$ -37.55M$ -47.49M$ -34.44M$ -7.83M$ -21.37M
Net Non Operating Interest Income Expense
$ 2.36M$ 1.11M$ 237.00K$ 466.00K$ 0.00-
Other Income Expense
$ 150.00K$ 1.12M--$ 262.00K$ 643.00K
Pretax Income
$ -66.98M$ -65.94M$ -47.25M$ -33.98M$ -7.83M$ -20.73M
Tax Provision
$ 9.02M$ 9.02M----
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -66.98M$ -65.94M$ -47.25M$ -33.98M$ -7.83M$ -20.73M
Basic EPS
$ -5.90$ -5.86$ -4.21$ -4.70$ -2.57$ -8.10
Diluted EPS
$ -7.54$ -5.86$ -4.21$ -4.70$ -2.57$ -8.10
Basic Average Shares
$ 33.88M$ 11.25M$ 11.23M$ 7.23M$ 5.84M$ 2.56M
Diluted Average Shares
$ 45.14M$ 11.26M$ 11.23M$ 7.23M$ 5.84M$ 2.56M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 39.84M$ -67.06M$ 47.49M$ 34.44M$ 7.83M$ 21.37M
Net Income From Continuing And Discontinued Operation
$ -66.98M$ -65.94M$ -47.25M$ -33.98M$ -7.83M$ -20.73M
Normalized Income
$ -7.69M-$ -47.25M$ -33.98M$ -7.83M$ -21.16M
Interest Expense
$ 274.00K-$ 1.74M$ 34.00K--
$ -67.25M$ -65.94M$ -45.52M$ -33.94M$ -7.83M$ -21.37M
$ -65.00M$ -63.18M$ -45.40M$ -33.84M$ -7.81M$ -21.26M
Currency in USD

Protara Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis